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DOI 10.1016/j.ccr.2011.06.003SUMMARYLoss-of-function mutations affecting one or both copies of the Ten-Eleven-translocation (TET)2 gene have
been described in various humanmyeloidmalignancies.We report that inactivation of Tet2 inmouse perturbs
both early and late steps of hematopoiesis including myeloid and lymphoid differentiation in a cell-autono-
mous manner, endows the cells with competitive advantage, and eventually leads to the development of
malignancies. We subsequently observed TET2 mutations in human lymphoid disorders. TET2 mutations
could be detected in immature progenitors endowed with myeloid colony-forming potential. Our results
show that the mutations present in lymphoid tumor cells may occur at both early and later steps of lymphoid
development and indicate that impairment of TET2 function or/and expression predisposes to the develop-
ment of hematological malignancies.Significance
TET2 mutations were associated with all subtypes of human myeloid malignancies. We show that Tet2 deficiency in mouse
results in a cell-autonomous competitive advantage of hematopoietic progenitors, widespread hematological defects, and
myeloid transformation. We also demonstrate that TET2 mutations can be identified in human B and T cell lymphomas.
These mutations can affect the hematopoietic stem cell compartment and may appear as an early event in the multistep
process that leads to lymphoid or myeloid or both malignancies. These observations indicate that therapeutic strategies
may have to target the hematopoietic stem cells to eradicate these diseases.
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TET2 Is Inactivated in Human LymphomasINTRODUCTION
Most human adult cancers develop through a multistep acqui-
sition of a wide range of somatic mutations. It has been
proposed that the tumor cells that initiate or maintain the malig-
nant clone need to be able to self-renew. In human acute
leukemia, this crucial property can be acquired by committed
progenitors with limited self-renewal capacities through
a genetic event or maintained through the targeting of hemato-
poietic stem cells (HSCs) (Cozzio et al., 2003; Goardon et al.,
2011; Huntly et al., 2004). Leukemia-initiating cells are able to
reconstitute the leukemia upon xenotransplantation in immuno-
deficient mice (Dick, 2008). Such cells have been experimen-
tally shown to represent 1/102–1/106 of the original blastic
population in human acute myeloblastic and lymphoblastic
leukemia. This notion, however, does not indicate the origin
of the cell, namely, the cell in which the initial tumorigenic event
occurred. Despite important progress in the identification of
oncogenes involved in the development of human mature
lymphoid malignancies, little is known regarding the initiating
events in these diseases. More specifically, the natural history
of mature T-lymphoid neoplasms is poorly understood (Jaffe,
2009; Jones, 2010).
The TET family proteins (Tet1, Tet2, Tet3) have been shown
to catalyze the conversion of 5-methyl-cytosine (mC) to 5-hy-
droxymethyl-cytosine (hmC), a recently identified epigenetic
mark (Ito et al., 2010; Koh et al., 2011; Kriaucionis and Heintz,
2009; Tahiliani et al., 2009). We and others have recently
identified mutations in the TET2 gene that frequently repre-
sent an early event during the development of a wide variety
of human myeloid malignancies, including myeloproliferative
neoplasms (MPNs), polycythemia vera (PV), essential throm-
bocythemia (ET), myelofibrosis (MF), myelodysplastic syn-
drome (MDS), chronic myelomonocytic leukemia (CMML),
and acute myeloid leukemia (AML) (Abdel-Wahab et al.,
2009; Delhommeau et al., 2009; Jankowska et al., 2009; Kohl-
mann et al., 2010; Kosmider et al., 2009a, 2009b; Langemeijer
et al., 2009; Nibourel et al., 2010; Tefferi et al., 2009a, 2009b,
2009d). A correlation between low hmC and TET2 mutation
status was reported in patients with MDS (Ko et al., 2010b),
suggesting that an altered 5-hydroxy-methylation status in
promoter or imprinted region leads to deregulation of impor-
tant hematopoietic regulators and participates to the malig-
nant process.
In half of the patients, only one copy of TET2 is mutated,
arguing for a role of haploinsufficiency in transformation (Del-
hommeau et al., 2009; Langemeijer et al., 2009). The variety of
myeloid disorders carrying a TET2 mutation suggests that it
may represent an early step in the transformation process, tar-
geting the hematopoietic stem/progenitor cell compartment.
TET2 mutation may, however, also occur at late steps during
the transformation of MPN to secondary acute leukemia
(Abdel-Wahab et al., 2010; Beer et al., 2010; Couronne´ et al.,
2010; Saint-Martin et al., 2009; Schaub et al., 2010).
To investigate the role of TET2 during hematopoiesis, we
engineered two mouse models in which the 5-hydroxy-methyla-
tion function of Tet2 is impaired. In addition, we investigated
the status of TET2 coding sequences in various human mature
lymphoid malignancies.26 Cancer Cell 20, 25–38, July 12, 2011 ª2011 Elsevier Inc.RESULTS
Murine Models of Tet2 Inactivation
We generated two Tet2-deficient mouse lines (Figure 1A). One
was derived from a gene-trap ES clone (SIGTR ES cell line
AN0709) in which a b-galactosidase-neomycin cassette was
inserted in Tet2 intron 9 (Tet2LacZ allele), thus leading to the
expression of a Tet2-bGal fusion transcript (Figure 1A). We
also generated a conditional knockout allele of Tet2 in which
the coding sequences of the last exon of Tet2 are surrounded
by loxP sites (Tet2Lox). After Cre recombination, this allele
results in the loss of the last 490 carboxy-terminal (Ct) amino
acids of Tet2. In both models, TET2 is predicted to lose the
conserved Ct homology region of the double-stranded b-helix-
2OG-Fe(II)-dependent dioxygenase domain. The two alleles
were backcrossed for at least six generations into the C57BL/6
background, and then intercrossed to obtain homozygous
animals.
Mice bearing the conditional Tet2 allele and the interferon
inducible Cre transgene (Mx1-Cre) were intercrossed to obtain
a cohort of Mx1-Cre+Tet2Lox/Lox (hereafter named Tet2/) and
control Mx1-Cre-Tet2Lox/Lox (hereafter named Tet2+/+) animals
that were injected with poly(dI-dC) to induce Cre expression
and acute inactivation of Tet2 in adult animals. Full excision
was observed in bonemarrow and thymus (Figure 1B) and corre-
lated with loss of normal Tet2 mRNA expression in purified
hematopoietic stem (Lineage-Sca-1+c-Kit+: LSK cells) and pro-
genitor populations (Figure 1C).
Tet2LacZ/LacZ animals were obtained at aMendelian ratio, were
fertile and appeared normal (data not shown). Tet2LacZ/LacZ
progenitors showed a 20%–50% residual expression of a normal
Tet2mRNA compared to wild-type progenitors, suggesting that
the Tet2LacZ allele is an hypomorph allele (Figure 1D; see Fig-
ure S1 available online). Importantly, Tet1 and Tet3 expression
levels remained unchanged in progenitors from both models
(Figures 1C and 1D). Quantification of mC and 5hmC in Tet2/
lineage- cells revealed amarked reduction of 5hmC compared to
Tet2+/+ (Figures 1E and 1F). Using a similar approach, no signif-
icant change in 5hmC level was detected in Tet2LacZ/LacZ lineage-
cells (data not shown). Together these data confirmed the inac-
tivation of Tet2 in these models and indicate that loss of Tet2
during adult hematopoiesis is not compensated by increased
transcription of Tet1 and Tet3.
Tet2 Controls Hematopoietic Stem and Progenitor Cells
Homeostasis
Analysis of the hematopoietic compartments in these animals
showed an amplification of the LSK compartment in 4- to 6-
month-old animals in both Tet2 inactivation models (Figures 2A
and 2B; Figures S2A–S2D). Heterozygous animals also pre-
sented increased LSK in both models (Figures S3A and S3F).
Within this compartment, CD34+Flt3- short-term stem cells and
to a lesser extent CD34-Flt3- long-term stem cells were ampli-
fied. Notably, absolute numbers of CD150+CD48- LSK cells
were slightly increased (Figure 2A; Figure S2D). The absolute
number of common myeloid progenitors (CMP) and megakaryo-
cyte-erythrocyte progenitors (MEP) was increased, whereas
the granulocyte-macrophage progenitor (GMP) population
remained stable in Tet2/ animals compared with controls
Figure 1. Description of the Two Tet2 Inactivation Mouse Models
(A) Partial structure of the Tet2 gene. For the Tet2LacZ ‘‘LacZ’’ allele, the location of the gene-trap cassette containing a splice acceptor and a b-galactosidase-
neomycin fusion gene is indicated (empty triangle). For the Tet2Lox ‘‘floxed’’ allele, loxP sites (black triangles) have been introduced in intron 10 and in the
30 untranslated region of exon 11.
(B) PCR analyses of Mx1-Cre-mediated exon 11 deletion in peripheral blood leukocytes (PBL), bone marrow (BM), spleen (Spl) and thymus (Th) cells from
Mx1-Cre-Tet2Lox/Lox (hereafter named Tet2+/+) and Mx1-Cre+Tet2Lox/Lox (hereafter named Tet2/) animals 2 months after poly(dI:dC) injections (floxed allele:
305 bp; deleted allele: 237 bp).
(C) Quantitative RT-PCR analysis of expression of the murine Tet1, Tet2 and Tet3 genes in flow-sorted hematopoietic progenitors from Tet2+/+ and Tet2/
animals (n = 3 per genotype). Results are normalized with respect to Abl1 expression and represented relatively to expression in control mice samples. Tet2
RT-PCR assay spans the exon 10–11 boundary. LSK: Lin-Sca-1+c-Kit+; CMP: common myeloid progenitor; MEP: megakaryocyte-erythrocyte progenitor; GMP:
granulocyte-macrophage progenitor.
(D) Quantitative RT-PCR analysis in Tet2LacZ/LacZ versus wild-type controls as in C (n = 3 per genotype).
(E) Drop in 5-hydroxymethyl-cytosine (5hmC) in immature populations of Tet2-inactivatedmice. Immunoblot analyses of increased quantity of genomic DNA from
BM lineage (lin)-negative cells of Tet2+/+ and Tet2/ mice 4 months after poly(dI:dC) induction using anti 5-methylcytosine- (5mC) antibody (left panel) and
5-hydroxymethyl-cytosine- (5hmC) antibody (right panel).
(F) Quantification of the signal shown in (E).
See also Figure S1.
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Figure 2. Tet2 Regulates Hematopoietic Stem and Progenitor Compartments Homeostasis
(A) Flow cytometrical analysis of hematopoietic stem and progenitor cells in the bonemarrow of Tet2+/+ and Tet2/ animals. Analysis was performed 4–6months
postinduction. Percentages within lineage- bone marrow cells (left panel), myeloid progenitor cells (MProg: lin-Sca-1-c-Kit+ cells; middle left panel), or within LSK
cells (lin-Sca-1+c-Kit+ cells; middle right and right panel) are indicated.
(B) Representation of the results exemplified in A as a percentage of lineage-negative hematopoietic progenitors. Data are presented as mean ± SEM Tet2+/+
(n = 6; white histogram) and Tet2/ (n = 6; black histogram) mice.
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TET2 Is Inactivated in Human Lymphomas(Figures S2E and S2K). Bone marrow cells from Tet2/ animals
presented a functional increase in methylcellulose colony form-
ing progenitors (Figure 2C; Figures S2F and S2G). Of note, the
average number of cells per colony was higher in Tet2-deficient
cell cultures compared with controls (Figures S2F and S2M).
Culture of purified LSK cells from some Tet2/ animals
12 months after induction also produced an increased number
of cells presenting a decreased differentiation toward
CD11b+Gr1+ myeloid cells and a higher maintenance of the
immature c-Kit+Sca1+ phenotype compared with controls
(Figures S2H and S2I). The amplitude of this phenotype was vari-
able among animals. Similar results were obtained from gene-
trap animals (Figures S2J–S2N).
To demonstrate the cell-autonomous nature of this pro-
perty, we transplanted total bone marrow or purified LSK cells
from both Tet2-deficient models (CD45.2+CD45.1-) in com-
petition with wild-type cells (CD45.2+CD45.1+) into wild-type
CD45.2-CD45.1+ recipients. Homozygous Tet2-deficient cells
from both models efficiently reconstitute all hematopoietic line-
ages for over 16 weeks, indicating that amplified LSK cells are
functional (Figures 2D–2H; Figures S2O–S2S). In both myeloid
and lymphoid lineages, the contribution of Tet2-deficient cells
progressively increased over that of wild-type cells. An amplifi-
cation of the LSK compartment was observed in some recipient
animals (Figure S2R).
Together, these data showed that Tet2 inactivation resulted in
a phenotypic and functional amplification and a competitive
advantage of hematopoietic stem and progenitor cells indicating
cell-autonomous control of their homeostasis by Tet2.
Tet2 Inactivation Induces Alteration of Several Mature
Hematopoietic Lineages
To further characterize the consequences of Tet2 inactivation on
mature hematopoietic lineages, we followed a cohort of Tet2/,
Tet2LacZ/LacZ animals and their respective controls for disease
development. Four-month-old Tet2/ and Tet2LacZ/LacZ animals
present amodest increase in white blood cell counts, a decrease
in erythroid and platelets counts, and a significant hepatospleno-
megaly compared with controls (Figures 3A and 3B; Figures S3H
and S3I). Histopathological analysis showed an alteration of the
normal splenic architecture with significant expansion of the red
pulp and infiltration of the lymphoid follicles with admixed
maturing myeloid, immature erythroid, and maturing megakar-
yocytic elements (Figure S3L; Figure 3C). Analysis of the liver
showed that Tet2/ animals presented a diffuse infiltration of(C) Clonogenic activity of bone marrow (BM), spleen (Spl) and peripheral blood (P
4–8months postinduction in methylcelluloseM3434medium. Colonies were score
also Figure S2.
(D) Competitive bone marrow transplantation (BMT) assay. CD45.2+ donor BM ce
lethally irradiated CD45.1+ recipients, in equivalent number to wild-type compet
cells) in the blood is given at the indicated time points post-BMT (n = 2 mice per
(E) Percentage of CD45.2+ donor chimerism in blood cells 20weeks post-BMT; my
or CD8+). Values shown are mean ± SEM (n = 2 mice per genotype).
(F) Representative flow cytometrical profiles of donor chimerism in blood subpop
(G) LSK cells transplantation. CD45.2+ sorted-LSK cells isolated from Tet2-deficie
recipients. The percentage of donor chimerism in the blood is given at the indic
genotype). See also Figure S2.
(H) Representative flow cytometrical analysis of donor chimerism in bone marro
CD71+ erythroid cells; CD19+B220+ B cells).the sinusoids with an admixture of lymphoid and trilineage
myeloid elements with some focused perivascular infiltrations
(Figure S3L).
Flow cytometrical analysis confirmed an amplification of
myeloid cells in both models with a marked increase in a myelo-
monocytic CD11b+Gr1- population in the peripheral blood and
spleen (Figure 3D). Alteration of the erythroid lineage was
observed in the bone marrow with a significant increase in
CD71+Ter119- proerythroblasts and a decrease in the number
of CD71lowTer119+ late erythroblasts (Figure 3E). Splenic eryth-
ropoiesis was also visible with an increase in the number of
CD71+Ter119+ erythroid cells (Figure 3E). Tet2-deficient spleno-
cytes could form multilineages colonies in methylcellulose
colony-forming assays confirming extramedullar hematopoiesis
(Figure 2C and data not shown). Similar abnormalities were
observed in the gene-trap model (Figures S2M, S2N, S3J,
and S3K).
Lymphoid lineages were also affected with a global increase in
the number of immature double-negative (DN) CD4-CD8- T cell
progenitors in the thymus, more particularly, CD44+CD25- DN1
cells (Figure 3F; Figures S3Q–S3V). The B cell lineage was also
altered with a decreased number of bone marrow B220+IgM-
pre- and pro-B cells and B220+IgMlow mature B cells (Figure 3G)
associated with an increase in the number of splenic B cells (Fig-
ure 3H; Figures S3M–S3P). Of note, heterozygous Tet2LacZ/wt
animals present similar abnormalities of the myeloid, erythroid
and B cell lineages (Figure S3B). Also, both lymphoid and
myeloid lineage alterations were observed in recipients of
Tet2-deficient cells (Figure S2O), indicating that differentiation
abnormalities are cell autonomous.
With age, some Tet2LacZ/wt and Tet2LacZ/LacZ animals devel-
oped a lethal phenotype associated with important weight
loss, high white blood cell counts, anemia, thrombocytopenia,
and massive hepatosplenomegaly (Figures 4A and 4B; data
not shown). Histopathological analysis of moribund animals
showed complete effacement of the spleen architecture and
massive perivascular as well as interstitial infiltration of the liver
with myeloid elements (Figure 4C). A moderate fibrosis, as-
sessed by increased reticulin fiber staining on tissue sections,
was observed in the spleen and liver but not the bone marrow
(Figure 4D). Flow cytometrical analysis confirmed the myeloid
and erythroid lineage hyperplasia with abnormal myelomono-
cytic differentiation revealed by a striking amplification of the
CD11b+Gr1- population visible in younger Tet2-deficient animals
(Figure 4E). Importantly, the disease was transplantable toB) cells from Tet2+/+ (n = 6; white circles) and Tet2/ (n = 6; black circles) mice
d after 7 days and results are represented asmean colony number ± SEM. See
lls isolated from Tet2+/+, Tet2LacZ/LacZ and Tet2/mice were transplanted into
itor CD45.1+CD45.2+ BM cells. The percentage of donor chimerism (CD45.2+
genotype). See also Figure S2.
elomonocytic cells (My; CD11b+Gr-1+), B cells (CD19+B220+) and T cells (CD4+
ulations shown in (E) (host cells were electronically excluded with CD45.1).
nt or wild-typemice were transplanted into lethally irradiated CD45.1+ congenic
ated time points post-BMT. Values shown are mean ± SEM (n = 2 mice per
w subpopulations 16 weeks post-BMT (CD11b+Gr-1+ myelomonocytic cells;
Cancer Cell 20, 25–38, July 12, 2011 ª2011 Elsevier Inc. 29
Figure 3. Tet2 Inactivation Results in Aberrant Myeloid and Lymphoid Maturation
(A) White blood cell (WBC), red blood cell (RBC), hematocrit (Ht), hemoglobin (Hb), and platelet (Plt) counts in peripheral blood samples obtained from Tet2+/+,
Tet2+/, and Tet2/ mice, performed 4–6 months postinduction. See also Figure S3 and Table S1.
(B) Spleen and liver weights of mutant and littermate control mice.
(C) VonWillebrandstainingon spleen sections fromTet2+/+ andTet2/animals highlightsmegakaryocytic hyperplasia inTet2/animals 4monthspostinduction.
Cancer Cell
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and a similar phenotype (Figure S4). To date, Tet2/ animals
did not develop lethal disorders with a follow-up of over
15 months.
Together, these results show that Tet2 inactivation in mice
results in pleiotropic alterations of the immature and mature
hematopoietic compartments including both lymphoid and
myeloid lineages (summarized in Table S1). With time, Tet2 inac-
tivation leads to bona fide myeloid malignancies with differentia-
tion abnormalities reminiscent of human CMML.
TET2 Is Mutated in Human Lymphoid Malignancies
Based on these results indicating that TET2 controls both self-
renewal and/or proliferation of early progenitors and also late
steps of both myeloid and lymphoid hematopoietic differentia-
tion, we investigated whether human lymphoid malignancies
could also present TET2 mutations. Supporting this hypothesis,
two of six patients presenting myeloid malignancies and initially
investigated for TET2 alterations, concomitantly suffered from
lymphomas (Delhommeau et al., 2009; Viguie´ et al., 2005).
Therefore, we resequenced the entire coding sequence of
TET2 in a series of human lymphoid malignancies. No nucleotide
changes inducing truncation or aminoacid changes in the cata-
lytic domain of TET2 were observed in chronic lymphocytic
leukemias (CLLs) (n = 75), plasma cell neoplasms (PCNs)
(n = 22), and leukemic or disseminated T cell neoplasms
(n = 45) [including T cell prolymphocytic leukemia (TPLL), T cell
large granular lymphocytic leukemias (TGLLs), and adult T cell
lymphoma/leukemia HTLV1+ (ATLL HLTV1)]. In a series of 301
B cell lymphoma and 177 T cell lymphoma samples, TET2muta-
tions were observed in 2.0% of B cell and 11.9% of T cell
lymphomas and in up to a third of the angioimmunoblastic
T cell lymphoma (AITL) samples (Table 1). The mutations were
mainly insertion/deletions, generating frameshifts and nonsense
mutations, as seen for myeloid malignancies (Table S2). Of note,
five of these patients had a known history of successive hemato-
logical malignancies (Table S3).
We also analyzed T-lymphoma samples by DNAmicro-arrays,
including nine TET2 wild-type and ten TET2 mutated samples.
The analysis revealed that one of the mutated samples also ex-
hibited a small genomic deletion of chromosome 4q including
the TET2 locus (Figure S5A). Therefore, as for myeloid malignan-
cies, TET2 genomic abnormalities are less frequent than TET2
mutations but may occur in conjunction.(D) Representative flow cytometrical analysis of the mature myeloid cells in the bo
total cells are indicated. Lower panel: absolute number of cells from analysis show
represented as mean ± SEM. See also Table S1.
(E) Representative flow cytometrical analysis of the erythroid lineage in the bone
indicated. Lower panel: absolute number of cells from analysis shown in (D). Tet2
as mean ± SEM.
(F) Representative flow cytometry analysis of thymocytes in Tet2+/+ and Tet2/m
total thymocytes are indicated. Upper right panels: the percentages of thymocyte
Lineage antibodies included antibodies against CD19, CD33, CD8, TCR-b, NK
CD4-CD8- DN in total thymocytes and CD44+CD25- DN1 cells in DN precursor thy
as mean ± SEM. See also Figure S3.
(G) Flow cytometrical analysis of B cells in the bone marrow of Tet2+/+ and Tet2/
gated on CD19+ cells (the frequencies are indicated as a percentage of CD19+
B cells (B220low IgMhi) and mature B cells (B220hi IgMhi). Lower panels indicate m
(H) Flow cytometrical analysis of splenic B cells in Tet2+/+ and Tet2/ animals. LMatched nontumoral DNA samples were available for 13
patients with TET2 mutations (Figure 5A, Table S2, Figures
S5B and S5C). The TET2 sequences were wild-type in two
patients (patients 5 and 6). The mutated TET2 sequence
detected in the lymphoma cells was clearly observed in the non-
tumoral DNA samples of five patients (patients 3, 4, 13, 15,
and 26). In two of them (patients 3 and 15), this might be due
to the presence of tumor cells, as judged by PCR analyses for
TCR or IgH clonality or the presence of IGH-BCL2 fusion tran-
script (data not shown). Trace of the mutated TET2 sequence
was suspected in six matched samples (patients 2, 10, 16, 17,
20, and 21) of which three (patients 2, 10, and 16) were devoid
of tumor cells. Mutations observed in patients 17, 20, and 25
have been described as acquired in myeloid malignancies.
Together the mutated TET2 sequences were observed in the
matched sample despite the absence of detectable circulating
tumor cells in five samples (patients 2, 4, 10, 13, and 16). In two
of these samples (patients 4 and 13), the estimated burden of
mutated sequences was comparable to the wild-type sequence.
Two hypotheses could account for these observations: either
the mutation was germline transmitted, or the mutation was
acquired and had endowed the clone with a growth advantage
over wild-type progenitors, leading to a skewed hematopoiesis.
TET2 Mutations Are Detected in CD34+ Cells
with Myeloid Potential
To test the hypothesis that TET2 mutations may arise in early
hematopoietic progenitors in patients presenting lymphomas,
we analyzed three patients for which viable cells were available.
Patient 8 was diagnosed with an AITL and carried a Q1445X
mutation. Bloodmononuclear cells were grown in a colony assay
supporting myeloid differentiation. Of the 11 colonies that grew
out, 5 showed only a wild-type TET2 allele and 6 showed both
Q1445X and wild-type alleles (Figure 5B). These results demon-
strate the acquired nature of the TET2 mutation in this patient
and also indicate its presence in progenitor cells with myeloid
colony-forming potential.
Patient 2 was initially diagnosed with a B cell lymphoma
carrying two TET2 mutations [(E448fs; 4663+1G > A: splice site
mutation)] that were barely detectable in blood sample (Fig-
ure 5C). Five months after treatment, the patient developed an
MDS that rapidly evolved into AML. Viable bone marrow cells
were available only at the AML phase. DNA was extracted from
whole bone marrow cells, purified CD34- and CD34+ fractions.ne marrow, spleen, and blood of Tet2+/+ and Tet2/ animals. Percentages of
n in (C). Tet2+/+ (n = 10; white bars) and Tet2/ (n = 16; black bars) animals are
marrow and spleen of Tet2+/+ and Tet2/ animals. Percentage of total cells is
+/+ (n = 10; white bars) and Tet2/ (n = 16; black bars) animals are represented
ice performed 4 months postinduction. Upper left panels: the percentages of
s precursors in Lineage-CD4-CD8- double-negative (DN) cells are represented.
-1.1, Ly-6G, and CD11b murine markers. Lower panels: the percentages of
mocytes from Tet2+/+ and Tet2/ animals (n = 3 per genotype) are represented
animals 4 months postinduction. Left panel: whole bone marrow. Right panel:
cells). Gates include pro- and pre-B precursor cells (B220low IgM-), immature
ean ± SEM of eight animals per genotype. See also Table S1.
ower panel indicate mean ± SEM of ten animals per genotype.
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Figure 4. Tet2 Inactivation Induces Fatal Hematopoietic Malignancies
(A) Kaplan-Meier survival curve of Tet2LacZ/LacZ animals and wild-type littermate controls. Only animals that reached moribund state were considered. See also
Figure S4.
(B) Representative picture of spleens observed in mutant Tet2LacZ/LacZ mouse compared with spleens from wild-type littermates.
(C) Hematoxylin-Eosin-Safran (HES) staining of bone marrow, spleen and liver sections from a 14-month-old moribund Tet2LacZ/LacZ animal. See also Figure S3L.
(D) Reticulin staining of spleen from animal in (C).
(E) Flow cytometrical analysis of myelomonocytic, erythroid, B and T lymphoid lineages in the spleen of a 14-month-old moribund mutant Tet2LacZ/LacZ mouse.
Of note, this animal displayed leukocytosis (69.1 3 106 WBC/mm3), anemia (1.76 3 106 RBC/mm3, 12.6% hematocrit, and 4.7 g hemoglobin/dl), thrombocy-
topenia (189 3 103 platelets/mm3) and hepatosplenomegaly (liver and spleen weights were 3960 and 2000 mg, respectively). See also Figure S4.
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seemingly variable ratios with respect to the wild-type sequence.
DNAwas extracted from28 colonies grown inmyeloid conditions
in vitro, from single CD34+ cells. Six colonies showed only wild-
type TET2 sequences, 14 colonies presented both TET2 muta-
tions, and 8 colonies carried only the splice site mutation (Fig-
ure 5C). Thesedata demonstrate the presenceof TET2mutations
inboth the lymphomaand theAMLcells, confirmed their acquired
nature. Taken together, theseobservations suggest that theTET2
mutated clone had invaded the bone marrow and was at the
origin of both the lymphoid and myeloid type malignancies.
Patient 27 was diagnosed with a T cell lymphoma. Bone
marrow aspirate examination was cytologically normal. We
observed two TET2 mutations (P761fs and Q481X) in the32 Cancer Cell 20, 25–38, July 12, 2011 ª2011 Elsevier Inc.CD34-CD3-CD19-CD14- cell fraction (the remaining fraction after
successive exclusion of the CD3+, CD19+ and CD14+ cell frac-
tions from the blood sample), which were absent in the other
fractions (Figure 6A). In vitro colonies assay of sorted CD34+
cells showed the presence of P761fs in 6 of 84 (7%) colonies,
whereas the stop mutation was not observed (Figure 6C). This
fraction remained stable, since a similar analysis showed 6 out
of 93 (6.5%) colonies with the P761fs mutation 4 months later.
Of the 45 colonies obtained from cultures of Lineage-CD34+
CD38- sorted cells, only one carried the P761fs (Figure 6C).
These results show the acquired nature of the TET2 mutations
in this patient and indicate the presence of a TET2 mutation on
one copy in a small fraction of hematopoietic progenitors with
myeloid differentiation potential.
Table 1. TET2 Mutations in B and T Cell Neoplasms
B cell ceoplasms All patients Mutated TET2
LPL 2 0 (0%)
PCN 22 0 (0%)
CLL /SLL 75 0 (0%)
TCRBL 3 0 (0%)
DLBCL 87 5 (5.7%)
MCL 22 0 (0%)
MZL 17 0 (0%)
FL 68 1 (1.5%)
Unspecified B-lymphoma 5 0 (0%)
Total 301 6 (2.0%)
T cell neoplasms All patients Mutated TET2
TLBL 5 1 (20%)
Leukemic or disseminated
(TPLL, TGLL, ATLL)
45 0 (0%)
Extranodal (ETCL, hepatosplenic) 4 0 (0%)
Extranodal cutaneous (Sezary, MF.) 42 2 (4.8%)
AITL 30 10 (33.3%)
ALCL 8 0 (0%)
PCTL, NOS 30 6 (20%)
Unspecified T-lymphoma 13 2 (15.4%)
Total 177 21 (11.9%)
LPL, lymphoplasmacytic lymphoma (including Waldenstro¨m macroglob-
ulinemia); PCN, plasma cell neoplasms (including plasma cell myeloma
and plasma cell leukemia); CLL, chronic lymphocytic leukemia; SLL,
small lymphocytic lymphoma; TCRBL, T cell-rich B cell lymphoma;
DLBCL, diffuse large B cell lymphoma; MCL, mantle cell lymphoma;
MZL,marginal zone lymphoma; FL, follicular lymphomal; TLBL: precursor
T-lymphoblastic lymphoma; TPLL, T cell prolymphocytic leukemia; TGLL,
T cell large granular lymphocytic leukemia; ATLL, adult T cell lymphoma/
leukemia (HTLV1+); ECTL, enteropathy-associated T cell lymphoma; MF,
mycosis fungoides; AITL, angioimmunoblastic T cell lymphoma; ALCL,
anaplastic large cell lymphoma; PCTL-NOS, peripheral T cell lymphoma
not otherwise specified.
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mutations in B and T cell lymphomas. Detailed analysis of three
patients indicated that lymphoma cells carried one somatic mu-
tation originally acquired in an hematopoietic stem cell. During
T cell maturation/differentiation, a second TET2 mutation may
occur, leading to the total loss of TET2 function in lymphoma
cells.
To investigate the sequence of events occurring during
tumor development, we further analyzed the tumor cells from
patient 27. SNP microarray analyses showed several acquired
abnormalities, including an LOH of the long arm of chromosome
7 and a duplication of the long arm of chromosome 4 (data not
shown). FISH analyses confirmed the presence of an additional
copy of the TET2 locus in 20% of the nuclei in blood sample
(data not shown). Sequencing of the PCR products obtained
from single cells, sorted in individual wells from the frac-
tion enriched in CD34-CD3-CD19-CD14- tumor cells, confirmed
the simultaneous presence of both TET2 mutations in 6/10
assays (Figure 6D). We also PCR-amplified a fragment spanning
the twomutations from the same tumor population, and the PCRproducts were subcloned using T/A vectors. Sequencing of indi-
vidual bacterial colonies showed that a given mutation was
always associated with a wild-type sequence at the other posi-
tion. The P761fs/Q481wt combination was observed 24/42
times (57%) and the P761wt/Q481X combination 18/42 times
(43%) (data not shown). No wild-type fragment was sequenced
from these vectors, indicating that all three TET2 copies present
in the tumor cells were mutated. The observed ratio between
both mutations indicated that the duplicated copy carried the
P761fs mutation. In addition, these data indicate that the flow-
sorted CD34-CD3-CD19-CD14- fraction contained essentially
tumor cells.
Additional genetic Alterations Are Associated
with TET2 Mutations
To identify additional genetic alterations in lymphomas, we used
an exome sequencing approach to investigate DNA from the
CD34-CD3-CD19-CD14- (tumor) and CD3+ (matched control)
fractions. For each fraction, exonic DNA was captured using
the SureSelect oligonucleotides (Agilent) and sequenced to
generate 115600653 and 90633228 reads, from tumor and
matched control libraries, respectively.
We first confirmed the presence of both TET2mutations in the
tumor population at a ratio of 184/339 reads (54%) for P761fs
and 140/389 reads (36%) for the Q481X, consistent with the
duplication of the P761fs mutation (Figure 6E). The two muta-
tions were observed at very low frequencies in the CD3+ fraction
(8/228 reads (4%) and 6/256 (2%) reads, respectively). We next
looked for sequence variations, with respect to the human refer-
ence sequence, that were present only in the tumor population.
Variations in seven genes (IGSF21, CRIM1, CLSTN2, MCCC2,
PLZF, ZC3H10, and ZNF774) were validated by Sanger analysis
(Figure 6E; Figure S6).
We then used quantitative RT-PCR to analyze the expression
profile of the mutated genes in RNA from normal human brain,
bone marrow, peripheral lymphocytes, and in flow-sorted tumor
cells from patient 27 (Figure 6F). CLSTN2 expression was
observed in brain, but not in normal PBL, thymus, or bonemarrow
nor inpatient’s tumorsamples (datanot shown).The lackofdetect-
able expression ofCLSTN2 in the hematopoietic system suggests
that the CLSTN2 mutation could be a passenger rather than
a causal mutation. The transcription of ZNF774, CRIM1, and
IGSF21was not detected in normal blood cells and/or in the tumor
sample, but was observed in the bone marrow and/or thymus,
questioning their role in the transformation process. Finally, we
investigated the presence of the mutations in the CD34+-derived
colonies of the patient. Mutations in PLZF andCRIM1were identi-
fied in eight of eight CD34+-derived colonies with the TET2P761fs
mutation. TheZNF774mutationwasobserved in six of eightTET2-
mutated colonies tested, suggesting that it occurred later in the
transformation process than the three others (i.e., TET2, PLZF,
and CRIM1). ZNF774, PLZF, and CRIM1 mutations were not
observed in 65 TET2 wild-type CD34+ colonies, suggesting that
they did not occur independently of the TET2 P761fs mutation.
DISCUSSION
The present study demonstrates the unique role of Tet2 during
murine hematopoiesis. Using two independent murine models,Cancer Cell 20, 25–38, July 12, 2011 ª2011 Elsevier Inc. 33
Figure 5. TET2 Mutation in Human
T-Lymphoma Samples
(A) TET2 sequence in diagnostic and matched
control samples. Vertical arrows indicate the
sequence variations. Other examples are shown in
Figure S5. Horizontal arrows hang over the
frameshift mutations. The presence of the mutated
TET2 sequences was confirmed by sub cloning the
PCR product from patient 10. The [1893_1896
delAAGC] (on the left) was observed on 1/29 DNA
molecules analyzed and the [4527 delG] (on the
right) was observed on 2/18 DNA molecules
analyzed.
(B) Genotype of CD34+ colonies from patient 8.
Note that four erythroid lineage colonies were
carrying the TET2 mutation.
(C) Genotyping of diagnostic and purified bone
marrow fractions and CD34+ colonies from
patient 2.
Left panel: TET2 sequences at the lymphoma
phase. Wild-type (WT) sequences are shown at the
top. Node: nodal biopsy at diagnosis.Whole-blood
sample was considered as normal matched DNA
because it is devoid of IGH clonal marker.
Right panel: TET2 sequences at the AML phase.
BM: bonemarrow nucleated cells. CD34-: negative
fraction after CD34+ beads selection and CD34+:
flow-sorted CD34+ population. Both mutations
(frameshift [fs] and splice site mutation) are
observed in all analyzed fractions.
Bottom: Genotype of colonies obtained from
single cells sorted on CD34 and CD38 expression.
4663+1G > A would have appeared first in the
course of the disease. Note that the cloning effi-
ciency was extremely low (less than one colony out
of 3000 seeded cells) and that colonies were small.
See also Figure S5 and Table S2.
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TET2 Is Inactivated in Human Lymphomaswe showed that alteration of Tet2 function resulted in pleiotropic
hematopoietic abnormalities and predisposed to development
of a fatal disorder resembling human myeloid disorders in which
TET2 is mutated. In addition, these results led to a screen that
identified TET2 mutations as a recurrent event in several human
lymphoid malignancies.
First, we show that complete inactivation of the catalytic
domain of Tet2 (conditional model) lead to a reduction of the
5hmC marks in hematopoietic cells. It has been postulated34 Cancer Cell 20, 25–38, July 12, 2011 ª2011 Elsevier Inc.that hmC might represent a step toward
cytosine demethylation, but opposite
data have been reported regarding the
relation between hmC and mC levels in
human samples (Figueroa et al., 2010;
Ko et al., 2010a). It will be important to
further investigate this point in the light
of the recent description of DNMT3A
mutation in human AML (Ley et al.,
2010). Tet2 also controls homeostasis of
murine hematopoietic stem and progen-
itor cells, in keeping with the reported
role of TET2 in ES cell differentiation
(Koh et al., 2011). Indeed, both Tet2-defi-
cient models present an amplification ofthe hematopoietic stem/progenitor cell population in vivo asso-
ciated with a competitive advantage in bone marrow transplan-
tation assays and an increased self-renewal in vitro. Importantly,
the gene-trap/hypomorph and conditional models exhibit some
differences. For example, the gene-trap animals develop bona
fide myeloid tumors that are transplantable to secondary recipi-
ents, whereas conditional animals did not develop fatal disease
during the 15 months of follow-up. In keeping with the observa-
tion that TET2 is mutated in half of human CMML patients
Figure 6. TET2 and Other Acquired Mutations Are Found in Hematopoietic Progenitors
(A) TET2 mutation status in flow-sorted subpopulations from blood samples from patient 27. The TET2 sequences in sorted subpopulations are shown. Both
mutations are detected in the CD3- and CD34-CD3-CD19-CD14- populations, whereas only P761fs is observed as a trace (indicated by a star) in the other
fractions.
(B) Summary of results presented in (A).
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TET2 Is Inactivated in Human Lymphomas(Kohlmann et al., 2010; Kosmider et al., 2009b; Tefferi et al.,
2009c), these results demonstrate that alteration of Tet2 func-
tions contribute to the development of hematologic disorders
with characteristics reminiscent of human CMML. Of note, we
did not detect global alteration of 5hmC levels in the lineage-
cells of the gene-trapmodel. It is possible that undetected subtle
reduction of 5hmC marks is sufficient for the alteration of the
hematopoietic progenitor compartment observed in both
models. The observation that heterozygous animals present
similar hematopoietic abnormalities supports this idea.
However, we cannot exclude that susceptibility to transforma-
tion is controlled by another function of Tet2, as proposed
recently for Tet1. Together, these results demonstrate that inac-
tivation of Tet2 catalytic function and deregulation of 5hmC
marks alter homeostasis of the hematopoietic progenitors and
warrant further studies of Tet2 expression level and structure in
inactivation models.
Second, we observed that Tet2 inactivation alters also T and
B cell differentiation in mice. Of note, we observed the amplifi-
cation of an aberrant CD19+B220low lymphoid population. We
demonstrated that, in human malignancies, TET2 is mutated
in 2.0% of B cell, 11.9% of T cell lymphomas and 30% of
AITL samples. Extensive molecular and cellular analyses
showed that TET2 mutations are present in cells endowed
with both myeloid and lymphoid potential in at least, a fraction
of the TET2-mutated lymphoma patients. In some lymphoma
patients, hematopoietic stem cells present mutation of one
TET2 allele in hematopoietic stem cells while lymphoma cells
present mutation of both copies. Deep resequencing of the
exome in a T cell lymphoma patient identified several mutations
that are present with TET2 mutation(s) either at the stem/
progenitor cell level or only at latter steps of lymphoma develop-
ment. Among those identified in early hematopoietic progenitor
cells (i.e., PLZF, CRIM1, and ZNF774), PLZF has previously
been shown to play a role in early hematopoietic progenitor
biology (Dick and Doulatov, 2009). Although functional analyses
will be required to assess the role of these mutations in
lymphoma progression, these data suggest that TET2 hemizy-
gous mutation cooperates with additional mutations, including
mutation of the second TET2 copy. These findings suggest
that in both mouse and human fine-tuning of TET2 expression
and activity is essential for normal homeostasis of the hemato-
poietic system and that loss of one allele of TET2 contribute to
disease development.
Finally, our results support the idea that disruption of Tet2
function leads to alteration of the homeostasis within the hema-
topoietic stem/progenitor compartment but per se does not
induce a specific hematopoietic malignancy. We propose that
Tet2 alteration, when it occurs in a stem/progenitor cell,
predisposes to the development of malignancies in cooperation
with secondary mutations that drives the phenotype of the(C) Genotype of colonies obtained from sorted single CD34+ cells. 1 and 2 corres
mutation is observed in CD34+ (7%) and CD34+CD38- (2.2%) colonies. No P7
colonies (data not shown).
(D) Single-cell analyses show the presence of both TET2 mutations in the same
(E) Somatic mutations identified through exome analyses of patient 27.
(F) Expression level of the mutated genes in normal tissues and tumor sample. E
See also Figure S6 and Table S3.
36 Cancer Cell 20, 25–38, July 12, 2011 ª2011 Elsevier Inc.disease. Combination of Tet2 deficiency with oncogenes, such
as JAK2V617F, will shed light on the oncogenic cooperation
observed in human tumorigenesis.EXPERIMENTAL PROCEDURES
Generation of the Tet2LacZ and Tet2floxed Alleles and Animal
Analyses
Gene-trap mouse embryonic stem cell clone (SIGTR ES cell line AN0709:
Tet2Gt(AN0709)Wtsi, herein named Tet2LacZ) carrying a b-galactosidase-neo-
mycin (b-geo) resistance fusion cassette in Tet2 gene were obtained from
UC Davis Mutant Mouse Regional Resource Center (http://www.mmrrc.org)
to generate gene-trap mouse line and the insertion of the b-geo cassette in
intron 9 of Tet2 was routinely genotyped on tail DNA by multiplexed poly-
merase chain reaction (PCR) using 50-CAGCCAGGAAGACACTTACC-30 and
50-GACACCGATCTTGCTGGTTG-30 primers into intron 9 to detect wild-type
Tet2 allele and 50-CGCCTTGCAGCACATCCC-30 and 50-GGCCTTCCTGTA
GCCAGC-30 primers into the b-galactosidase sequence (and after the splicing
donor site) to detect gene-trap allele (Tet2LacZ/LacZ).
Mice harboring Tet2 allele with exon 11 flanked by two loxP sites introduced
in intron 10 and in the 30 untranslated region of exon 11 (Tet2Lox/Lox; ‘‘floxed
allele’’) were generated by the Clinique de la Souris (Strasbourg, France) and
intercrossed with mice expressing Cre recombinase under the control of the
type I interferon-inducible Mx1 murine promoter (transgene referred as
Mx1-Cre). PCR on tail DNA using 50-GGCAGAGGCATGTTGAATGA-30 and
50-TAGACAAGCCCTGCAAGCAAA-30 primers allowed to distinguish between
wild-type and floxed allele. The Tet2Lox allele was backcrossed into C57BL/6
background for at least six generations using speed-congenics (Harlan Labo-
ratories) prior to analysis.
Acute inactivation of Tet2 in 6- to 10-week-old Mx1-Cre+Tet2Lox/Lox was
performed by intraperitoneal injections (three injections every other day) of
800 mg poly(I:C)-LMW (InvivoGen, San Diego). Induction of Cre recombinase
and efficient excision of floxed allele was confirmed by multiplex PCR using
50-GGCAGAGGCATGTTGAATGA-30, 50-TAGACAAGCCCTGCAAGCAAA-30
and 50-GTGTCCCACGGTTACACACG-30 primers that discriminated be-
tween floxed and deleted allele, respectively 305 and 237 bp. Therefore,
we used the following nomenclature: Mx1-Cre+Tet2Lox/Lox = Tet2/,
Mx1-Cre-Tet2Lox/Lox = Tet2+/+.
Competitive transplantations were performed by transplanting equal
numbers of total bone marrow cells from CD45.1-CD45.2+ Tet2-deficient and
CD45.1+CD45.2+ wild-type animals into lethally irradiated CD45.1+CD45.2-
recipients. For LSK cells transplantation, LSK cells were purified by flow
cytometry from Tet2-deficient animals and 4000 LSK cells supplemented
with 1 3 106 total bone marrow cells from wild-type were injected to lethally
irradiated recipients. Expression of CD45.1 and CD45.2 was followed by flow
cytometry on blood cells every month and animals were analyzed at 4 months
after transplantation.
Animal experiments were conducted according to the Institut Gustave
Roussy Institutional guidelines and authorized by the Direction De´partemen-
tale des Services Ve´te´rinaires du Val de Marne.Patient Samples Collection
Lymph node, peripheral blood, and bone marrow samples from the patients
were obtained with their informed consent and the approval of the local
Research Ethics Committees (Centre Henri Becquerel, Pitie´-Salpe´trie`re, and
Cochin hospitals). Additional information on patient samples is available in
Tables S2 and S3.pond to two successive blood samples at a 4-month interval. Only the P761fs
61fs positive colony was observed out of 40 CD34+CD38+ single-cell-derived
cell.
xpression levels were normalized with respect to GUSB expression.
Cancer Cell
TET2 Is Inactivated in Human LymphomasFlow Cytometry, Cell Sorting, and Purification
Total white blood cells, obtained from peripheral blood after lysis of red blood
cells, and single-cell suspensions from bone marrow, spleen and thymus were
stained in toto in PBS supplemented with 2% fetal bovine serum (FBS) with
fluorochrome-conjugated mouse antibodies raised against specific markers
of hematopoietic lineages (BD Biosciences PharMingen, except otherwise
mentioned). Additional information on antibody clones is available in Supple-
mental Methods. Viability of cells was confirmed by using the Sytox Blue
(Invitrogen) viability marker. Flow cytometric analysis and cell sorting were
performed using a FACSCantoII Flow Cytometer (BD Biosciences) and
a MoFlow (Becton Dickinson) or a FACSAriaIII (BD Biosciences), respectively.
Immunophenotypic data were analyzed using the FlowJo Version 7.2.4 soft-
ware (TreeStar).
For human samples, bone marrow or peripheral blood mononuclear cells,
lymphocytes, and granulocytes were isolated and stored in liquid nitrogen
as viable cells in FBS with 10% dimethyl-sulfoxide (DMSO, Sigma). Patients
were selected on DNA availability. Their clinical and biological characteristics
are summarized in Table S2. Diagnoses were made by standard international
criteria. Cells were purified using Miltenyi beads according the manufacturer
instructions. When mentioned, cells were sorted after labeling with PE–CD34
and APC–CD38 antibodies (Immunotech) using a FACSDiva cell sorter (Becton
Dickinson).
In Vitro Clonogenic Assays
SortedCD34+ cells were seeded at one cell per well onmethylcellulose inMEM
alpha medium supplemented with 10% FBS (Stem Cell Technologies), and
a cocktail of early cytokines (thrombopoietin [TPO], interleukin [IL-3], Flt3-L,
Stem Cell Factor [SCF], erythropoietin [EPO], granulocyte-colony stimulating
factor [G-CSF], granulocyte/macrophage-colony stimulating factor [GM-
CSF] and IL-6). After 2 weeks, individual clones were collected for further
genotyping.
For patient 2, total mononuclear cells were seeded in 2% standard methyl-
cellulose supplemented with 25% FBS (Stem Cell Technologies), and a cock-
tail of cytokines as described.
Nucleic Acid Methods
DNA and RNAwere extracted using commercial kits (QIAGEN or Roche). Poly-
merase chain reaction (PCR) and direct sequencing reaction were performed
using standard conditions with primers available upon request. Nucleotide
sequences were compared to wild-type human genomic sequence present
in the databases (genome.ucsc.edu). All observed mutations were scored
on both strands. Additional information on exome sequencing is available in
Supplemental Experimental Procedures.
In Vitro Differentiation Assays
LSKs (5 3 102), total BM (5 3 104), and spleen cells (5 3 104) isolated from
mutant or control mice were cultured in methylcellulose-based medium (Me-
thoCult M3434; StemCell Technologies) and scored for CFUs (colony-forming
units) using combined scoring for burst-forming unit erythroids (BFU-Es), CFU-
megakaryocytes (CFU-Mks), CFU-granulocyte macrophages (CFU-GMs), and
CFU-granulocyte erythroid macrophage megakaryocytes (CFU-GEMMs) after
7 days. All live colonies were counted for each of the two 35 mm dishes plated
per sample.
Quantitative PCR
cDNA was synthesized from total RNA purified (using the RNeasy microkit,
QIAgen) from sorted LSK, common myeloid progenitor (CMP), megakaryo-
cyte-erythrocyte progenitor (MEP), and granulocyte-macrophage progenitor
(GMP) populations using the Superscript II reverse transcriptase (Invitrogen).
TaqMan probes were purchased from Applied Biosystems (Tet1:
Mm01169089; Tet2 [exon 9–10]: Mm00524395_m1; Tet2 [exon 10–11]:
Mm01312907; Tet3, Mm01184936; Abl1, Mm00802038). Tet2 (exon 3–4)
transcript were detected using the following primers; Primer1: 50-agaatcaga-
tactcctggtgaacaaa-30, Primer2: 50-cctagatgggtataataaggagcttcat-30, Probe:
50 FAM-tctggattgcatccttcacatttgccat-30TAM. Tet2-LacZ fusion transcript
was detected using the following primers and probe; Primer1 (Tet2 exon 9):
50-cccacagagaccagcagaaca-30, Primer2 (LacZ): 50-tgcgttcttcttctttggttttc-30,
Probe: 50FAM-cctgggaccactgtactgccatttgg-30TAM. The expression level ofeach gene was assessed by qRT-PCR with an ABI PRISM 7500 and cal-
culated following the DDCt method; each sample was analyzed in triplicate
and normalized with Abl1 and GusB expression (Applied Biosystems
Mm00802038_g1 and Mm03003537_s1, respectively).Statistical and Quantification Analyses
Results are expressed asmean values ± SEM. Statistical significance of differ-
ences between the results was assessed using a 2-tailed unpaired Student’s t
test, performed using Prism (GraphPad software, version 5.03). p values < 0.05
were considered statistically significant. Quantification of the 5mC and 5hmC
signals was performed by dot-blotting DNA and using antibodies from Euro-
gentec (1/500 dilution) and Active Motif (1/10,000 dilution) respectively. Signal
was quantified using GelEval (FrogDance software, version 1.32).ACCESSION NUMBERS
Microarray procedures and data used in this publication have been deposited
in the European Bioinformatics Institute (EBI) database with the following
accession number: E-TABM-1161.SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, three tables, and Supplemental
Experimental Procedures and can be found with this article online at doi:10.
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